ZandA Technologies

ZandA Technologies is a UK-based biotechnology company specializing in the development of next-generation gene therapies for neurodegenerative diseases. Founded as a spin-out from the University of Sheffield and Imperial College London, the company leverages the expertise of world-leading scientists in the field of viral vectors and gene delivery. Their primary focus is on utilizing proprietary Adeno-associated virus (AAV) platforms to deliver therapeutic genes effectively to the central nervous system. The company's pipeline targets high-need indications such as Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). ZandA aims to overcome current limitations in gene delivery to provide transformative, one-time treatments for patients with devastating neurological conditions.